Brightcove Enables BadaBusiness.com to Set Two New Guinness World Records for Largest Online Streaming Event
Brightcove Inc. (NASDAQ: BCOV), the world’s leading video technology platform, announced today that BadaBusiness.com, an ed-tech platform founded by Dr. Vivek Bindra, has set two new Guinness World Records for the largest online business and sales lessons streamed, which were powered by Brightcove. The live webinars were joined by BadaBusiness.com’s customers, as well as attendees looking to ‘learn and earn at home’ by exploring the means of upskilling, training, and acquiring new business knowledge. These webinars are a part of Dr. Vivek Bindra’s ‘India Revival Mission,’ which derived from the impact of COVID-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200621005050/en/
(Graphic: Business Wire)
The first webinar, titled Largest Online Business Lesson, had a previous record of 12,091 unique attendees, and on April 24, 2020, the stream set a new world record of 18,693 attendees. The second world record was set by BadaBusiness.com on May 31, 2020, when it debuted its Largest Online Sales Lesson webinar with 95,087 attendees. BadaBusiness.com will be hosting the World's Largest Strategy Session on June 27, 2020, to mark International MSME Day.
Brightcove helps organizations in more than 70 countries meet business challenges through its robust, scalable, and intuitive video platform. Powering BadaBusiness.com’s online events is yet another example of how organizations are pushing the boundaries by inspiring, entertaining, and engaging their audiences through video. According to live analytics data captured by Brightcove’s platform, BadaBusiness.com achieved peak traffic of over 2.3 million total video views, over 1.3 million unique viewers, and 345,000 peak concurrent users during the live event on May 31st.
“Our mission is to provide extensive knowledge of practical business strategies and frameworks to enterprises across India so they can grow and strengthen their brand. With video, BadaBusiness.com is able to host online webinars to deliver those important business messages, while also experiencing better engagement with our audiences,” said Dr. Vivek Bindra, Founder of BadaBusiness.com. “Not only is it an accomplishment to simultaneously bring together nearly 100,000 attendees who share similar business goals, but we also broke two Guinness World Records, all thanks to Brightcove’s technology.”
“At Brightcove, we are always working with our customers to pursue unique and innovative use cases of video. BadaBusiness.com’s online events demonstrate how video can offer educational and informative content, while also being one of the best ways to bring people together virtually,” said Charles Chu, Chief Product Officer, Brightcove. “We’re ecstatic that BadaBusiness.com now holds two world records for the largest online streamed events while choosing Brightcove to power those experiences for their audiences.”
About BadaBusiness.com
A technology-enabled training company that provides affordable, available and accessible business training programs to MSME Business Owners, Entrepreneurs and Wantapreneurs in vernacular language, through a combination of online and offline delivery mechanisms. The objective is to empower individual entrepreneurs and small businesses to scale up, by providing them tools and problem-solving support ecosystem.
About Brightcove Inc. (NASDAQ: BCOV)
We are the people behind the world’s leading video technology platform. With our award-winning technology and services, we help organizations in more than 70 countries meet business challenges and create strategic opportunities by inspiring, entertaining, and engaging their audiences through video.
Since Brightcove was established in 2004, we have consistently pushed boundaries to create a platform for people who are serious about video: one that is robust, scalable, and intuitive. Benefiting from a global infrastructure, unrivalled customer support, an extensive partner ecosystem, and relentless investment in R&D, Brightcove video sets the standard for professional grade video management, distribution, and monetization. To learn more, visit www.brightcove.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200621005050/en/
Contact information
Meredith Duhaime
Senior Public Relations Manager
Brightcove | 603-785-8518
mduhaime@brightcove.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom